Nanobac Announces Mayo Clinic Initial Results for Nanoparticle and Arterial Calcification Study
17:30 23.05.07
TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP)
("Nanobac" or "the Company)
announces that scientists at Mayo Clinic, working under a collaborative
agreement with Nanobac have cited evidence showing the presence of
calcifying nanoparticles (CNPs) in plaque-filled arteries in animal
models. This potentially represents a previously unrecognized factor in
the development of arteriosclerosis and calcific arterial disease.
The project seeks to determine if human derived nanoparticles are
pathogenic and induce inflammatory and calcific pathologic arterial
disease. Scientific evidence increasingly links arterial calcification
to the presence of nanosized particles. The project also seeks to
confirm prior Nanobac studies, conducted at Washington Hospital, that
Nanobacs diagnostic test specifically
identifies CNPs.
The studys author, Maria Kraemer, a Mayo
Graduate researcher in Rochester, Minn. stated, The
work we are doing with human-derived nanoparticles is important because
preliminary studies indicate that they may increase negative responses
to arterial injury, possibly leading to blocked arteries and arterial
calcification.
Dr. Maniscalco, co-chair of Nanobac, stated: We
believed that CNPs play a major role in pathologic calcification and a
multitude of associated disease states such as calcification of arteries
and organs. This study, conducted by one of the lead medical and
research facilities in the United States, lends credence to our beliefs.
About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals, Inc. is
dedicated to the discovery and development of products and services to
improve human health through the detection and treatment of calcifying
nanoparticles (CNPs), formerly known as nanobacteria. The company's
pioneering research is establishing the pathogenic role of CNPs in soft
tissue calcification, particularly in coronary artery, prostate and
vascular disease.
Nanobac's drug discovery and development is focused on new and existing
compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac
manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting
calcifying nanoparticles. IVD products include a line of assays,
proprietary antibodies and reagents for uniquely recognizing CNPs.
Nanobac's BioAnalytical Services works with biopharmaceutical partners
to develop and apply methods for avoiding, detecting, and inactivating
or eliminating CNPs from raw materials.
Experimental Biology is an annual scientific meeting convened by the
Federation of American Societies of Experimental Biology, including the
American Association of Anatomists; American Physiological Society;
American Society for Biochemistry and Molecular Biology; American
Society for Investigative Pathology; American Society for Nutrition; and
the American Society for Pharmacology and Experimental Therapeutics.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For
more information, visit our website at:
http://www.nanobac.com.Investors are cautioned that certain statements in this document, some
statements in periodic press releases and some oral statements of
Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements"
within the meaning of the Private Securities Litigation Reform Act of
1995 (the "Act"). Forward-Looking statements include statements which
are predictive in nature, which depend upon or refer to future events or
conditions, which include words such as "believes," "anticipates,"
"intends," "plans," "expects," and similar expressions. In addition, any
statements concerning future financial performance (including future
revenues, earnings or growth rates), ongoing business strategies or
prospects, and possible future Nanobac Pharmaceuticals, Inc. actions,
which may be provided by management, are also forward-looking statements
as defined by the Act. Forward-Looking statements involve known and
unknown risks, uncertainties, and other factors which may cause the
actual results, performance or achievements of the Company to materially
differ from any future results, performance or achievements expressed or
implied by such forward-looking statements and to vary significantly
from reporting period to reporting period. Although management believes
that the assumptions will, in fact, prove to be correct or that actual
future results will not be different from the expectations expressed in
this report. These statements are not guarantees of future performance
and Nanobac Pharmaceuticals, Inc. has no specific intention to update
these statements.
Thread abonnieren
ETF-Sparplan